Electrochemical miRNA-34a-based biosensor for the diagnosis of Alzheimer’s disease

Pereira, Raquel L.; Oliveira, Daniela; Pêgo, Ana P.; Santos, Sofia D.; Moreira, Felismina T.C.

doi:10.1016/j.bioelechem.2023.108553

Cited by 11 publications

(5 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, each miRNA node within the cluster can potentially regulate multiple lncRNAs and lncRNA interactors, implying a complex regulatory network that warrants further exploration. For example, while miR-34a-5p has been shown to be upregulated in AD patients' brains [39], it is also known to target the 3 UTR region of tau, reducing its expression [40]. In contrast to its upregulation in AD, miR-34a-5p is downregulated in mouse brains following traumatic brain injury (TBI) [41].…”

Section: Discussionmentioning

confidence: 99%

Exploring Circulating Long Non-Coding RNAs in Mild Cognitive Impairment Patients’ Blood

De Felice,

Coppola,

Bonavita

et al. 2023

Biomedicines

View full text Add to dashboard Cite

Mild cognitive impairment (MCI) is a transitional clinical stage prior to dementia. Patients with amnestic MCI have a high risk of progression toward Alzheimer’s disease. Both amnestic mild cognitive impairment and sporadic Alzheimer’s disease are multifactorial disorders consequential from a multifaceted cross-talk among molecular and biological processes. Non-coding RNAs play an important role in the regulation of gene expression, mainly long non-coding RNAs (lncRNAs), that regulate other RNA transcripts through binding microRNAs. Cross-talk between RNAs, including coding RNAs and non-coding RNAs, produces a significant regulatory network all through the transcriptome. The relationship of genes and non-coding RNAs could improve the knowledge of the genetic factors contributing to the predisposition and pathophysiology of MCI. The objective of this study was to identify the expression patterns and relevant lncRNA-associated miRNA regulatory axes in the blood of MCI patients, which includes lncRNA-SNHG16, lncRNA-H19, and lncRNA-NEAT1. Microarray investigations have demonstrated modifications in the expression of long non-coding RNAs (lncRNA) in the blood of patients with MCI compared with control samples. This is the first study to explore lncRNA profiles in mild cognitive impairment blood. Our study proposes RNAs targets involved in molecular pathways connected to the pathogenesis of MCI.

show abstract

Section: Discussionmentioning

confidence: 99%

Exploring Circulating Long Non-Coding RNAs in Mild Cognitive Impairment Patients’ Blood

De Felice,

Coppola,

Bonavita

et al. 2023

Biomedicines

View full text Add to dashboard Cite

show abstract

“…A study conducted by Pereira et al demonstrated that a novel electrochemical miRNA biosensor, developed using nanotechnology, exhibited high targeting affinity and specific detection capabilities for miR-34a. This provides a new, economic, and less invasive diagnostic tool for early detection of AD [ 106 ]. Chiu utilized immunomagnetic nanoparticle techniques to measure Aβ and tau proteins in plasma.…”

Section: Applications Of Nanomaterials On Aging-related Nanodiagnosti...mentioning

confidence: 99%

Classification and applications of nanomaterials in vitro diagnosis

Lai,

Huang,

Weng

et al. 2024

Heliyon

View full text Add to dashboard Cite

“…Pereira et al . constructed an electrochemical biosensor for miRNA detection based on two gold nanostructure-modified carbon screen-printed electrodes (C-SPEs) and an oligonucleotide probe for miR-34a, which showed a linear range of 100 pM - 1 μM, with a detection limit of 94 aM in serum [ 73 ].…”

Section: Biological Diagnostic Approachmentioning

confidence: 99%

Diagnosis of Alzheimer's disease: Towards accuracy and accessibility

Mu,

Chang,

Chen

et al. 2024

J Biol Methods

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is a serious dementia afflicting aging population and is characterized by cognitive decline, amyloid-β plaques, and neurofibrillary tangles. AD substantially impairs the life quality of the victims and poses a heavy burden on the society at large. The number of people with dementia due to AD, prodromal AD, and preclinical AD is estimated to stand at roughly 3.2, 69, and 315 million worldwide, respectively. Current clinical diagnosis is based on clinical symptoms, and clinical research demonstrated that positron emission tomography (PET) and cerebrospinal fluid (CSF) biomarkers had excellent diagnostic performance. However, the application of CSF biomarker tests and PET are restricted by the invasiveness and high cost. The presence of clinical symptoms means that AD pathology has been progressing for many years, and only a few drugs have been approved for the traetemnt of AD. Therefore, early diagnosis is extremely important for controlling the outcomes caused by AD. In this review, we provided an overview of developing clinical diagnostic criteria, diagnostic strategies under clinical research, developing blood based-biomarker assays, and promising nanotechnologically-based assays.

show abstract

Electrochemical miRNA-34a-based biosensor for the diagnosis of Alzheimer’s disease

Cited by 11 publications

References 46 publications

Exploring Circulating Long Non-Coding RNAs in Mild Cognitive Impairment Patients’ Blood

Exploring Circulating Long Non-Coding RNAs in Mild Cognitive Impairment Patients’ Blood

Classification and applications of nanomaterials in vitro diagnosis

Diagnosis of Alzheimer's disease: Towards accuracy and accessibility

Contact Info

Product

Resources

About